131 related articles for article (PubMed ID: 27163847)
1. KAI1(CD82)-DARC(CD234) axis in the stem cell niche.
Hur J; Baek SH; Kim HS
Cell Cycle; 2016 Aug; 15(15):1945-7. PubMed ID: 27163847
[No Abstract] [Full Text] [Related]
2. CD82/KAI1 Maintains the Dormancy of Long-Term Hematopoietic Stem Cells through Interaction with DARC-Expressing Macrophages.
Hur J; Choi JI; Lee H; Nham P; Kim TW; Chae CW; Yun JY; Kang JA; Kang J; Lee SE; Yoon CH; Boo K; Ham S; Roh TY; Jun JK; Lee H; Baek SH; Kim HS
Cell Stem Cell; 2016 Apr; 18(4):508-21. PubMed ID: 26996598
[TBL] [Abstract][Full Text] [Related]
3. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression.
Bandyopadhyay S; Zhan R; Chaudhuri A; Watabe M; Pai SK; Hirota S; Hosobe S; Tsukada T; Miura K; Takano Y; Saito K; Pauza ME; Hayashi S; Wang Y; Mohinta S; Mashimo T; Iiizumi M; Furuta E; Watabe K
Nat Med; 2006 Aug; 12(8):933-8. PubMed ID: 16862154
[TBL] [Abstract][Full Text] [Related]
4. The palmitoylation of metastasis suppressor KAI1/CD82 is important for its motility- and invasiveness-inhibitory activity.
Zhou B; Liu L; Reddivari M; Zhang XA
Cancer Res; 2004 Oct; 64(20):7455-63. PubMed ID: 15492270
[TBL] [Abstract][Full Text] [Related]
5. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration.
Zhang XA; He B; Zhou B; Liu L
J Biol Chem; 2003 Jul; 278(29):27319-28. PubMed ID: 12738793
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of cancer stem cells marked by CD133 and KAI1/CD82 expression in laryngeal squamous cell carcinoma.
Yu L; Zhou L; Wu S; Gong X; Feng Z; Ma L; Zhu B; Yao N; Wang D; Dong H
World J Surg Oncol; 2014 Apr; 12():118. PubMed ID: 24758564
[TBL] [Abstract][Full Text] [Related]
7. EWI2/PGRL associates with the metastasis suppressor KAI1/CD82 and inhibits the migration of prostate cancer cells.
Zhang XA; Lane WS; Charrin S; Rubinstein E; Liu L
Cancer Res; 2003 May; 63(10):2665-74. PubMed ID: 12750295
[TBL] [Abstract][Full Text] [Related]
8. Effect of KAI1/CD82 on the beta1 integrin maturation in highly migratory carcinoma cells.
Jee BK; Lee JY; Lim Y; Lee KH; Jo YH
Biochem Biophys Res Commun; 2007 Aug; 359(3):703-8. PubMed ID: 17560548
[TBL] [Abstract][Full Text] [Related]
9. Tetraspanin CD82 inhibits protrusion and retraction in cell movement by attenuating the plasma membrane-dependent actin organization.
Liu WM; Zhang F; Moshiach S; Zhou B; Huang C; Srinivasan K; Khurana S; Zheng Y; Lahti JM; Zhang XA
PLoS One; 2012; 7(12):e51797. PubMed ID: 23251627
[TBL] [Abstract][Full Text] [Related]
10. KAI1/CD82, a tumor metastasis suppressor.
Liu WM; Zhang XA
Cancer Lett; 2006 Aug; 240(2):183-94. PubMed ID: 16260083
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane interactions are needed for KAI1/CD82-mediated suppression of cancer invasion and metastasis.
Bari R; Zhang YH; Zhang F; Wang NX; Stipp CS; Zheng JJ; Zhang XA
Am J Pathol; 2009 Feb; 174(2):647-60. PubMed ID: 19116362
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of the expression of KAI1/CD82 and PDGFRβ and their impact on glioma progression.
Paradowski M; Bilinska M; Bar J
Folia Neuropathol; 2016; 54(3):241-248. PubMed ID: 27764516
[TBL] [Abstract][Full Text] [Related]
13. Metastasis suppressor KAI1/CD82 attenuates the matrix adhesion of human prostate cancer cells by suppressing fibronectin expression and β1 integrin activation.
Lee HA; Park I; Byun HJ; Jeoung D; Kim YM; Lee H
Cell Physiol Biochem; 2011; 27(5):575-86. PubMed ID: 21691075
[TBL] [Abstract][Full Text] [Related]
14. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favorable prognostic factor: an immunohistochemical analysis.
Higashiyama M; Kodama K; Yokouchi H; Takami K; Adachi M; Taki T; Ishiguro S; Nakamori S; Yoshie O; Miyake M
Cancer; 1998 Aug; 83(3):466-74. PubMed ID: 9690539
[TBL] [Abstract][Full Text] [Related]
15. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma.
Uchida S; Shimada Y; Watanabe G; Li ZG; Hong T; Miyake M; Imamura M
Br J Cancer; 1999 Mar; 79(7-8):1168-73. PubMed ID: 10098753
[TBL] [Abstract][Full Text] [Related]
16. Correlation of KAI1/CD82 gene expression with good prognosis in patients with non-small cell lung cancer.
Adachi M; Taki T; Ieki Y; Huang CL; Higashiyama M; Miyake M
Cancer Res; 1996 Apr; 56(8):1751-5. PubMed ID: 8620488
[TBL] [Abstract][Full Text] [Related]
17. KAI1/CD82 expression as a prognosic factor in sporadic colorectal cancer.
Muneyuki T; Watanabe M; Yamanaka M; Shiraishi T; Isaji S
Anticancer Res; 2001; 21(5):3581-7. PubMed ID: 11848527
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Detection Between Pancreatic Cancer and Liver Metastasis Nude Mouse Models Constructed by Using the PANC1-KAI1/CD
Wang S; Chen J; Li H; Qi X; Liu X; Guo X
Technol Cancer Res Treat; 2021; 20():15330338211045204. PubMed ID: 34605330
[No Abstract] [Full Text] [Related]
19. Expression of KITENIN, a KAI1/CD82 binding protein and metastasis enhancer, in bladder cancer cell lines: relationship to KAI1/CD82 levels and invasive behaviour.
Rowe A; Jackson P
Oncol Rep; 2006 Dec; 16(6):1267-72. PubMed ID: 17089048
[TBL] [Abstract][Full Text] [Related]
20. The maintenance mechanism of hematopoietic stem cell dormancy: role for a subset of macrophages.
Chae CW; Choi G; Kim YJ; Cho M; Kwon YW; Kim HS
BMB Rep; 2023 Sep; 56(9):482-487. PubMed ID: 37574807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
